BR112014016157A8 - derivados heterobicíclicos como inibidores de vhc - Google Patents

derivados heterobicíclicos como inibidores de vhc

Info

Publication number
BR112014016157A8
BR112014016157A8 BR112014016157A BR112014016157A BR112014016157A8 BR 112014016157 A8 BR112014016157 A8 BR 112014016157A8 BR 112014016157 A BR112014016157 A BR 112014016157A BR 112014016157 A BR112014016157 A BR 112014016157A BR 112014016157 A8 BR112014016157 A8 BR 112014016157A8
Authority
BR
Brazil
Prior art keywords
inhibitors
vhc
heterobicyclic derivatives
relates
present
Prior art date
Application number
BR112014016157A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014016157A2 (pt
Inventor
Vandyck Koen
Jean-Marie Bernard Raboisson Pierre
Gaston Verschueren Wim
Original Assignee
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland
Publication of BR112014016157A2 publication Critical patent/BR112014016157A2/pt
Publication of BR112014016157A8 publication Critical patent/BR112014016157A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112014016157A 2011-12-28 2012-12-27 derivados heterobicíclicos como inibidores de vhc BR112014016157A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11195840 2011-12-28
PCT/EP2012/076934 WO2013098313A1 (en) 2011-12-28 2012-12-27 Hetero-bicyclic derivatives as hcv inhibitors

Publications (2)

Publication Number Publication Date
BR112014016157A2 BR112014016157A2 (pt) 2017-06-13
BR112014016157A8 true BR112014016157A8 (pt) 2017-07-04

Family

ID=47505011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016157A BR112014016157A8 (pt) 2011-12-28 2012-12-27 derivados heterobicíclicos como inibidores de vhc

Country Status (12)

Country Link
US (1) US9126986B2 (OSRAM)
EP (1) EP2797911B1 (OSRAM)
JP (1) JP6170944B2 (OSRAM)
CN (1) CN104203940B (OSRAM)
AU (1) AU2012360905B2 (OSRAM)
BR (1) BR112014016157A8 (OSRAM)
CA (1) CA2858659A1 (OSRAM)
ES (1) ES2558608T3 (OSRAM)
IN (1) IN2014MN01465A (OSRAM)
MX (1) MX340033B (OSRAM)
RU (1) RU2621734C1 (OSRAM)
WO (1) WO2013098313A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520822A (ja) 2011-07-09 2014-08-25 スンシネ ルアケ プハルマ カンパニー リミテッド Ｃ型肝炎ウイルス阻害剤としてのスピロ化合物
CN104169271B (zh) * 2011-12-28 2017-04-05 爱尔兰詹森科学公司 作为hcv抑制剂的喹唑啉酮衍生物
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
CN104860931A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 丙肝病毒抑制剂及其制药用途
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN108349945B (zh) * 2015-11-06 2021-10-29 江苏豪森药业集团有限公司 Hcv抑制剂、其制备方法与应用
CN106946775B (zh) * 2016-01-07 2020-04-10 清华大学 一种化合物及其在制备抗丙肝病毒药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
KR100652535B1 (ko) 1999-03-19 2006-12-01 버텍스 파마슈티칼스 인코포레이티드 Ｉｍｐｄｈ 효소의 억제제
JP4832647B2 (ja) 1999-03-26 2011-12-07 ユーロ−セルティック エス． ア． アリール置換ピラゾール、イミダゾール、オキサゾール、チアゾールおよびピロール、ならびにそれらの使用
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030005443A1 (en) 2001-06-27 2003-01-02 Karin Axelsson EPG having PIP window history and sample view functionality
EA008148B1 (ru) 2002-06-19 2007-04-27 Биовитрум Аб Новые соединения, их применение и получение
EP1532118A2 (en) 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2007000706A2 (en) 2005-06-29 2007-01-04 Koninklijke Philips Electronics N.V. Block signature based data transfer
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
WO2007039578A1 (en) 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted azabenzophenone compounds
TW200800969A (en) 2005-12-22 2008-01-01 Smithkline Beecham Corp Compounds
NO324811B1 (no) 2005-12-22 2007-12-10 Norsk Hydro Produksjon As Undervannspumpe
ATE534632T1 (de) 2006-04-11 2011-12-15 Vertex Pharma Thiazole, imidazole und pyrazole als proteinkinasehemmer
FR2900404B1 (fr) 2006-04-27 2008-07-18 Sod Conseils Rech Applic Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA200970375A1 (ru) 2006-10-13 2009-10-30 Президио Фармасьютикалз, Инк. Соединения и способы лечения вируса гепатита с
JP2010510245A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
GB0707092D0 (en) 2007-04-12 2007-05-23 Smithkline Beecham Corp Compounds
NZ587323A (en) 2008-02-12 2012-02-24 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102007122B (zh) 2008-02-13 2013-09-04 百时美施贵宝公司 作为丙型肝炎病毒抑制剂的咪唑基联苯基咪唑
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20110098779A (ko) * 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Ｈｃｖ ｎｓ5ａ의 억제제
WO2010065674A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
AU2010217797B2 (en) 2009-02-27 2014-02-20 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104016971B (zh) 2009-05-13 2016-05-25 吉利德制药有限责任公司 抗病毒化合物
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2550268A1 (en) * 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CN102869657A (zh) * 2010-03-24 2013-01-09 沃泰克斯药物股份有限公司 用于治疗或预防黄病毒感染的类似物
EA023642B1 (ru) * 2010-07-26 2016-06-30 Янссен Сайенсиз Айрлэнд Юси Гетеробициклические производные в качестве ингибиторов hcv

Also Published As

Publication number Publication date
EP2797911A1 (en) 2014-11-05
MX2014008041A (es) 2014-08-21
EP2797911B1 (en) 2015-10-28
AU2012360905A1 (en) 2014-06-26
AU2012360905B2 (en) 2017-04-27
WO2013098313A1 (en) 2013-07-04
MX340033B (es) 2016-06-21
RU2621734C1 (ru) 2017-06-07
BR112014016157A2 (pt) 2017-06-13
IN2014MN01465A (OSRAM) 2015-04-17
JP6170944B2 (ja) 2017-07-26
JP2015503536A (ja) 2015-02-02
CN104203940A (zh) 2014-12-10
US9126986B2 (en) 2015-09-08
US20140357626A1 (en) 2014-12-04
CA2858659A1 (en) 2013-07-04
ES2558608T3 (es) 2016-02-05
CN104203940B (zh) 2017-01-18

Similar Documents

Publication Publication Date Title
BR112014016157A8 (pt) derivados heterobicíclicos como inibidores de vhc
BR112015004192A2 (pt) sulfamoíl-arilamidas e o seu uso como medicamentos para o tratamento da hepatite b
BR112015028538A2 (pt) derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b
BR112015008325A2 (pt) compostos antivirais contra o rsv
BR112015020242A2 (pt) sulfamoil-arilamidas e seu uso como medicamentos para o tratamento da hepatite b
BR112015028461A2 (pt) derivados de sulfamoílpirrolamida e o seu uso como medicamentos para o tratamento da hepatite b
BR112012031561A2 (pt) morfolino pirimidinas e seu uso em terapia.
BR112015004161B8 (pt) Derivado bicíclico fusionado de sulfamoíla e seu uso no tratamento e prevenção de infecção por vírus da hepatite b, bem como composição farmacêutica e produto que o compreende
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
BR112014016808A8 (pt) composições de biguanida e métodos de tratamento de distúrbios metabólicos
BR112017028504A2 (pt) derivados de sulfamoilarilamida ciclizada e uso dos mesmos como medicamentos para o tratamento da hepatite b
BR112015025052A2 (pt) derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
BR112014029185A2 (pt) nucleosídeos de spirooxetano uracila
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
BR112013032391A2 (pt) antagonistas de trpv4
BR112015007742B8 (pt) composto, composição farmacêutica, e, uso do referido composto
BR112014030173A8 (pt) Composto derivado de benzimidazol-prolina, e, composição farmacêutica
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
BR112015017331A2 (pt) compostos químicos
BR112014015845A2 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BRPI0915887B8 (pt) derivados de indol macrocíclicos úteis como inibidores do vírus da hepatite c
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained
B350 Update of information on the portal [chapter 15.35 patent gazette]